We have received a letter, including several attachments, dated March 14, 2019, from Peter Cashin, Managing Director Huntleigh Healthcare limited, on March 19th 2019. The subject was "Notice relating to fetal monitoring practice" and it was addressed "To whom it may concern".

Huntleigh informs about the intention to circulate the letter and the attachments within 14 days to the "wider market place". We respond with an open letter "To whom it may concern" (in particular the editor of AJOG, DGGG guideline committee, BfArM) - and to interested recipients of Huntleigh's information package linked to the "Notice relating to fetal monitoring practice".

We would like to start by confirming that in general we highly respect the outstanding pioneering contributions of Drs. Dawes and Redman to the field of electronic fetal monitoring. We've carefully read and discussed Peter Cashin's letter and the attached letters from Dr. Richard Liwicki, Deputy Director, Research Services, Oxford University, Dr. James Pardey, first author of the "AJOG Paper" 2002;186:1095-1103, Dr. Adam Stoten, COO Oxford University Innovation, and Professor Emeritus Chris Redman, Oxford University, "co-inventor" of the "hidden variable" Dawes/Redman STV.

We came to the following two main conclusions.